Hsu Jason, Maguire Maureen G, Fine Stuart L
Scheie Eye Institute, Department of Ophthalmology, University of Pennsylvania, Philadelphia 19104, USA.
Can J Ophthalmol. 2005 Jun;40(3):320-31. doi: 10.1016/S0008-4182(05)80075-4.
Age-related macular degeneration (AMD) is the most common cause of severe and irreversible vision loss among people 50 years of age or older in many Western countries. Most of the available treatments for AMD are intended for the late stage, specifically for choroidal neovascularization (CNV). Effective preventive treatments could have an even greater impact on the vision of the millions of people at risk for vision loss from AMD. Drusen are typically the earliest lesions seen in patients with AMD and precede the development of CNV. In 1973, Gass noted the disappearance of drusen in eyes that received laser photocoagulation, which led to the hypothesis that laser-induced drusen reduction could alter the natural course of AMD.
We reviewed relevant articles found through a search of MEDLINE through February 2005 by means of the following key words, alone or in combination: drusen, laser, photocoagulation, age-related macular degeneration, macula and choroidal neovascularization.
Reports ranging from individual cases and case series to randomized controlled pilot studies have described various laser treatment protocols and their effects on eyes with high-risk drusen but no neovascular changes. These reports provide evidence that laser photocoagulation can induce drusen reduction. Although some investigators have reported a corresponding improvement in visual function, others have found no change or even worsening. The results in several of the larger randomized controlled studies suggest that CNV may occur at an increased rate in laser-treated eyes with high-risk drusen in patients who have neovascular AMD in the other eye. The long-term effects of laser treatment in patients with high-risk drusen in both eyes and no neovascular changes have yet to be determined.
The outcome of clinical trials such as the Prophylactic Treatment of Age-Related Macular Degeneration and the Complications of Age-Related Macular Degeneration Prevention Trial will help to determine the role of laser prophylaxis in patients with AMD.
年龄相关性黄斑变性(AMD)是许多西方国家50岁及以上人群严重且不可逆视力丧失的最常见原因。大多数现有的AMD治疗方法针对晚期,特别是针对脉络膜新生血管(CNV)。有效的预防性治疗可能对数百万有AMD致视力丧失风险的人的视力产生更大影响。玻璃疣通常是AMD患者最早出现的病变,先于CNV的发展。1973年,加斯注意到接受激光光凝治疗的眼睛中玻璃疣消失,这导致了激光诱导玻璃疣减少可改变AMD自然病程的假说。
我们通过以下关键词单独或组合检索截至2005年2月的MEDLINE,回顾相关文章:玻璃疣、激光、光凝、年龄相关性黄斑变性、黄斑和脉络膜新生血管。
从个别病例和病例系列到随机对照试验性研究的报告描述了各种激光治疗方案及其对有高危玻璃疣但无新生血管改变的眼睛的影响。这些报告提供了激光光凝可诱导玻璃疣减少的证据。虽然一些研究者报告了视觉功能相应改善,但其他研究者未发现变化甚至恶化。几项较大规模随机对照研究的结果表明,在另一只眼有新生血管性AMD的患者中,激光治疗的有高危玻璃疣的眼睛发生CNV的几率可能增加。双眼有高危玻璃疣且无新生血管改变的患者激光治疗的长期效果尚未确定。
诸如年龄相关性黄斑变性预防性治疗和年龄相关性黄斑变性预防试验并发症等临床试验的结果将有助于确定激光预防在AMD患者中的作用。